英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

subtrahend    
n. 减数

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA expands approval of Modernas RSV vaccine to some adults under age . . .
    The U S Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older
  • Moderna Receives U. S. FDA Approval for RSV Vaccine, mRESVIA, in Adults . . .
    Expanded indication builds on existing U S FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA ACCESS Newswire June 12, 2025 Moderna, Inc (NASDAQ:MRNA) today announced that the U S Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD
  • FDA expands approval for Modernas RSV vaccine - The Hill
    The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from
  • FDA expands Pluvicto’s prostate cancer indication
    On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with
  • FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid
    Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease
  • Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger . . .
    The US Food and Drug Administration (FDA) has expanded approval of Moderna’s respiratory syncytial virus (RSV) vaccine to include younger adults at risk, though its still uncertain whether the shot will be recommended for broader use in the national immunisation schedule Moderna’s vaccine, known under the brand name mRESVIA, became the first non-Covid-19 messenger RNA-based (mRNA) vaccine
  • FDA expands Modernas RSV vaccine approval to at-risk adults - MSN
    The U S Food and Drug Administration has approved Moderna’s (NASDAQ: MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 who
  • Moderna receives expanded approval for RSV vaccine - CIDRAP
    Vaccine maker Moderna said yesterday that it has received expanded approval from the Food and Drug Administration (FDA) for its respiratory syncytial virus (RSV) vaccine In a news release, Moderna said the FDA has approved mResvia (mRNA-1345) for the prevention of RSV in people ages 18 to 59 years old who are at increased risk for disease
  • U. S. FDA Approves Expanded Indication for AbbVies MAVYRET . . .
    It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis With this approval, MAVYRET is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate 2,†
  • Moderna wins FDA OK to widen use of RSV vaccine
    The Food and Drug Administration has approved wider use of Moderna’s respiratory syncytial virus vaccine in a boost for a company that’s been negatively impacted by the recent leadership changes atop U S public health agencies The shot, dubbed mResvia, was cleared on Thursday for adults aged 18 to 59 who are at high risk for increased risk of RSV-related disease Prior to the label





中文字典-英文字典  2005-2009